LifeSciences BC Announces New President and CEO to Lead Organization

April 15, 2019
LifeSciences BC

 Vancouver, BC – April 15, 2019, Nancy Harrison, Chair, LifeSciences BC Board of Directors, announced today the appointment of Wendy Hurlburt, as the organization’s new President and CEO. “We are very pleased to have Wendy join and lead our team; as she brings a strong business background in pharmaceutical, not-for-profit and operations management to this … Continue reading LifeSciences BC Announces New President and CEO to Lead Organization

Onestep Laboratories received a China patent CN107449902, potential to monitor Chlorine in dialysis for kidney failure

April 10, 2019
Onestep Laboratories Inc.

Onestep Laboratories, a biotech company that specializes in developing and producing raw material for immunoassay and other assays, received a China patent CN107449902, potentially for chlorine monitoring in dialysis for kidney failure. The company is developing a method for chlorine monitoring in dialysis. The current DPD method has many drawbacks. For example, the color produced … Continue reading Onestep Laboratories received a China patent CN107449902, potential to monitor Chlorine in dialysis for kidney failure

WAT Medical Returns Cruise Show with US Partner VIKAND

April 9, 2019
WAT Medical

WAT Medical is a company that develops safe, effective, and user-friendly wearable medical products.  With a team of devoted staff leading in the field of medical research and development, an efficient and convenient medical service is being provided for individual customers worldwide. The mission is supplying innovative self-care medical devices. There are two products on … Continue reading WAT Medical Returns Cruise Show with US Partner VIKAND

First AI Enabled ROI Radiation Reduction Shutter Technology FluoroShield™ Cleared by FDA

April 8, 2019
IKOMED Technologies Inc

Sanford, FL and Vancouver BC, April 2, 2019 – Omega Medical Imaging announces the launch of FluoroShield™FluroroShield in conjunction with technology partner IKOMED Technologies of Vancouver, BC Canada. FluoroShield™ is an Artificial Intelligence powered Region of Interest (ROI) Radiation exposure reduction solution for interventional X-ray imaging available only on Omega’s Flat Panel detector CS-series product … Continue reading First AI Enabled ROI Radiation Reduction Shutter Technology FluoroShield™ Cleared by FDA

DelMar Pharmaceuticals Welcomes Dr. John de Groot, Chairman, ad interim of the Department of Neuro-Oncology at MD Anderson Cancer Center, as founding member of the Company’s Scientific Advisory Board

April 4, 2019
DelMar Pharmaceuticals Inc.

Dr. Napoleone Ferrara, a Member of DelMar Pharmaceuticals Board Will Serve as the Chairman of the SAB VANCOUVER, British Columbia and MENLO PARK, Calif., April 4, 2019 /PRNewswire/ — DelMar Pharmaceuticals, Inc. (Nasdaq: DMPI) (“DelMar” or the “Company”), a biopharmaceutical company focused on the development and commercialization of new cancer therapies, announced today the formation of a … Continue reading DelMar Pharmaceuticals Welcomes Dr. John de Groot, Chairman, ad interim of the Department of Neuro-Oncology at MD Anderson Cancer Center, as founding member of the Company’s Scientific Advisory Board

PharmAust successfully reformulates cancer drug

April 3, 2019

April 3, 2019 – ASX-listed biotech PharmAust, has successfully managed to reformulate its potentially breakthrough cancer drug Monepantel after feedback from previous trials that the taste was unpalatable. The reformulation has now cleared the way for new canine clinical trials, a key milestone along the company’s drug development journey that is looking increasingly exciting. In … Continue reading PharmAust successfully reformulates cancer drug

GenXys Health Care Systems announces completion of oversubscribed seed round financing to launch leading precision prescribing software into the US market

GenXys

GenXys, a precision prescribing software company tackling a $130 billion global problem, is pleased to announce that it has closed its oversubscribed seed round at $1.77 million, with key investors TYDO and TELUS Ventures. Following early commercial success in Canada, this financing supports GenXys plans to expand into new regions to increase patient safety and medication … Continue reading GenXys Health Care Systems announces completion of oversubscribed seed round financing to launch leading precision prescribing software into the US market

DelMar Pharmaceuticals Receives Approval from MD Anderson Cancer Center’s IRB for Protocol Expansion to Include Maintenance Stage MGMT-unmethylated GBM Patients in Ongoing Phase 2 Trial of VAL-083

DelMar Pharmaceuticals Inc.

VANCOUVER, British Columbia and MENLO PARK, Calif., April 3, 2019 /PRNewswire/ — DelMar Pharmaceuticals, Inc. (Nasdaq: DMPI) (“DelMar” or the “Company”), a biopharmaceutical company focused on the development and commercialization of new cancer therapies, today announced the University of Texas MD Anderson Cancer Center’s (MDACC) Institutional Review Board (IRB) has approved a trial protocol amendment to expand … Continue reading DelMar Pharmaceuticals Receives Approval from MD Anderson Cancer Center’s IRB for Protocol Expansion to Include Maintenance Stage MGMT-unmethylated GBM Patients in Ongoing Phase 2 Trial of VAL-083

WAT Medical receives Interview from NHK, Japan’s National Broadcasting Organization

WAT Medical

NHK is one of the largest broadcasting corporations in Japan, providing international services on numerous TV programs, radio, and the Internet. Currently documenting on the advancements of neuromodulation technologies, in February 2019, the NHK production team has visited medical technology companies in Vancouver, Chicago and San Francisco. The development, use, and advancements of neuromodulation technologies … Continue reading WAT Medical receives Interview from NHK, Japan’s National Broadcasting Organization

CDRD and TRIUMF Announce Collaboration to Revolutionize the Fight Against Cancer with Targeted Alpha Therapy

April 2, 2019
CDRD

Vancouver, BC and Ottawa, ON – April 2, 2019: CDRD, Canada’s life sciences venture, TRIUMF, the country’s national particle accelerator centre, and TRIUMF Innovations, the centre’s commercialization arm have joined forces to advance and commercialize promising research in the field of novel radiopharmaceuticals. Speaking at the 11th International Symposium on Targeted Alpha Therapy (TAT 11) … Continue reading CDRD and TRIUMF Announce Collaboration to Revolutionize the Fight Against Cancer with Targeted Alpha Therapy